-
公开(公告)号：US20200299400A1
公开(公告)日：2020-09-24
申请号：US16612867
申请日：2018-05-24
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Nils LONBERG , Alan J. KORMAN , Mark J. SELBY , Bryan C. BARNHART , Aaron P. YAMNIUK , Mohan SRINIVASAN , Karla A. HENNING , Michelle Minhua HAN , Ming LEI , Liang SCHWEIZER , Sandra V. HATCHER , Arvind RAJPAL
IPC: C07K16/28
Abstract: Provided herein are heavy chain constant regions (referred to as “modified heavy chain constant regions”), or functionally equivalent fragments thereof, that enhance biological properties of antibodies relative to the same antibodies in unmodified form. An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge.
-
公开(公告)号：US20200268901A1
公开(公告)日：2020-08-27
申请号：US16849757
申请日：2020-04-15
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Nils LONBERG , Alan J. KORMAN , Mark J. SELBY , Bryan C. BARNHART , Aaron P. YAMNIUK , Mohan SRINIVASAN , Karla A. HENNING , Michelle Minhua HAN , Ming LEI , Liang SCHWEIZER , Sandra V. HATCHER , Arvind RAJPAL
IPC: A61K47/68 , A61K39/395 , C07K16/00 , C07K16/28 , C07K16/30
Abstract: Provided herein are heavy chain constant regions (referred to as “modified heavy chain constant regions”), or functionally equivalent fragments thereof, that enhance biological properties of antibodies relative to the same antibodies in unmodified form. An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge.
-
公开(公告)号：US20200262893A1
公开(公告)日：2020-08-20
申请号：US16751788
申请日：2020-01-24
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Dasa LIPOVSEK , Joseph TOTH , Ginger C. RAKESTRAW , Irvith M. CARVAJAL , Stanley Richard KRYSTEK, Jr. , Steven R. O'NEIL , Guodong CHEN , Richard Y. HUANG , Bryan C. BARNHART , John Thomas LOFFREDO , Christina TERRAGNI
Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.
-
公开(公告)号：US20190055320A1
公开(公告)日：2019-02-21
申请号：US16113061
申请日：2018-08-27
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Nils LONBERG , Alan J. KORMAN , Bryan C. BARNHART , Aaron P. YAMNIUK , Mohan SRINIVASAN , Karla A. HENNING , Ming LEI , Emanuela SEGA , Angela GOODENOUGH , Maria JURE-KUNKEL , Guodong CHEN , John S. SACK , Richard Y. HUANG , Martin J. CORBETT , Joseph E. MYERS, JR. , Liang SCHWEIZER , Sandra V. HATCHER , Haichun HUANG , Pingping ZHANG
IPC: C07K16/40 , G01N33/574 , A61K39/395 , A61K45/06 , C07K16/28 , C07K16/30 , A61K47/68 , A61K39/00
Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
-
公开(公告)号：US20180127513A1
公开(公告)日：2018-05-10
申请号：US15520638
申请日：2015-11-19
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Nils LONBERG , Alan J. KORMAN , Bryan C. BARNHART , Aaron P. YAMNIUK , Mohan SRINIVASAN , Karla A. HENNING , Ming LEI , Emanuela SEGA , Angela GOODENOUGH , Maria JURE-KUNKEL , Guodong CHEN , John S. SACK , Richard Y. HUANG , Martin J. CORBETT , Joseph E. MYERS, JR. , Liang SCHWEIZER , Sandra V. HATCHER , Haichun HUANG , Pingping ZHANG
IPC: C07K16/40 , G01N33/574 , A61K39/395 , A61K45/06 , C07K16/28 , C07K16/30 , A61K47/68 , A61K39/00
CPC classification number: C07K16/40 , A61K39/39558 , A61K45/06 , A61K47/6871 , A61K2039/505 , C07K16/2896 , C07K16/30 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/71 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , G01N33/57492 , G01N2333/916
Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.
-
Patent Agency Ranking
公开(公告)号：US20230312686A1
公开(公告)日：2023-10-05
申请号：US17985012
申请日：2022-11-10
Applicant: Bristol-Myers Squibb Company
Inventor： Dasa LIPOVSEK , Joseph TOTH , Ginger C, RAKESTRAW , Irvith M. CARVAJAL , Stanley Richard KRYSTEK, JR. , Steven R. O'NEIL , Guodong CHEN , Richard Y. HUANG , Bryan C. BARNHART , John Thomas LOFFREDO, III , Christina TERRAGNI
CPC classification number: C07K14/78 , A61K47/64 , A61K47/60 , A61K47/6435 , G01N33/6872 , A61K38/00
Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.
-
公开(公告)号：US20220324989A1
公开(公告)日：2022-10-13
申请号：US17694890
申请日：2022-03-15
Applicant: Bristol-Myers Squibb Company , CytomX Therapeutics, Inc.
Inventor： Bryan C. BARNHART , Brigitte DEVAUX , Aaron P. YAMNIUK , Shannon L. OKADA , Brenda L. STEVENS , James William WEST
Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40 and comprise improved heavy and light chain variable regions that impart improved yield and reduced aggregation. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
-
公开(公告)号：US20210054091A1
公开(公告)日：2021-02-25
申请号：US17091375
申请日：2020-11-06
Applicant: Bristol-Myers Squibb Company
Inventor： Bryan C. BARNHART , Brigitte DEVAUX , Aaron P. YAMNIUK , Shannon L. OKADA , Brenda L. STEVENS
Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for FcγRIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
-
公开(公告)号：US20200339700A1
公开(公告)日：2020-10-29
申请号：US16958563
申请日：2018-12-27
Applicant: Bristol-Myers Squibb Company , CytomX Therapeutics, Inc.
Inventor： Bryan C. BARNHART , Brigitte DEVAUX , Aaron P. YAMNIUK , Shannon L. OKADA , Brenda L. STEVENS , James William WEST
Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40 and comprise improved heavy and light chain variable regions that impart improved yield and reduced aggregation. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
-
公开(公告)号：US20240336695A1
公开(公告)日：2024-10-10
申请号：US18640480
申请日：2024-04-19
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Bryan C. BARNHART , Brigitte DEVAUX , Aaron P. YAMNIUK , Shannon L. OKADA , Brenda L. STEVENS
CPC classification number: C07K16/2878 , A61P31/12 , A61P35/00 , A61P35/02 , A61P35/04 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/72 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/75 , C07K2317/92 , C07K2317/94
Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for FcγRIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.017 seconds)
